Stock Market News
Takeda bumps up proposed offer for Shire
(WebFG News) - Shire received an improved takeover offer from Takeda Pharmaceutical on Friday, a day after turning down a £46.50 bid made up of shares and cash.
Takeda on Friday made a proposal to acquire FTSE 100-listed Shire for £47 per share, comprised of £21 cash paid in dollars and £26 of new Takeda shares.
This compared to the most recent proposal Shire rejected of £46.50 per share, comprised of £17.75 in cash and £28.75 shares.
The Japanese company said it believes that the newest proposal "represents a highly compelling opportunity for Shire shareholders" being a slight increase in total value and a "material increase" in the cash component.
Takeda said it intended to maintain its headquarters in Japan and primary listing on the Tokyo Stock Exchange and intends to put in place a NYSE listed ADR program on completion of any takeover to allow current Shire shareholders to continue to hold shares in the combined company.
The improved offer came a day after Dublin-headquartered US company Allergan said it was mulling a bid and then quickly decided, after an unimpressed shareholder reaction, that it wasn't.
As news of the improved offer broker on Friday, Shire shares essentially shrugged. Having earlier fallen more than 4% to below 3,800p after the Allergan interest faded, the price perked up 3,847.5p but could not hold that level for long.
Earlier on Friday, analysts at Societe Generale suggested that, based on recent takeover multiples in the sector, Takeda could raise its cash component by another £9 per Shire share from its £46.50 bid.
SocGen dissmised other potential suitors, saying neither Novartis nor AbbVie "strategically need" to buy Shire and that Pfizer is "no longer interested in transformational M&A", while Celgene and Allergan would have to raise so much new equity as to "excessively dilute" their earnings.
UBS also earlier pointed out that the deal is a "real financial stretch" for Takeda, which is likely to be "price sensitive".
The Swiss bank said it feels a deal "more likely than not a deal gets done, but who precisely does the deal remains murky", with the possibility that other bidders could still emerge and that Shire investors are likely to be "keen to avoid the regret they might feel if they don't sell and then the stock does badly" as regret avoidance "can be a powerful motivator".
Takeda on Friday made a proposal to acquire FTSE 100-listed Shire for £47 per share, comprised of £21 cash paid in dollars and £26 of new Takeda shares.
This compared to the most recent proposal Shire rejected of £46.50 per share, comprised of £17.75 in cash and £28.75 shares.
The Japanese company said it believes that the newest proposal "represents a highly compelling opportunity for Shire shareholders" being a slight increase in total value and a "material increase" in the cash component.
Takeda said it intended to maintain its headquarters in Japan and primary listing on the Tokyo Stock Exchange and intends to put in place a NYSE listed ADR program on completion of any takeover to allow current Shire shareholders to continue to hold shares in the combined company.
The improved offer came a day after Dublin-headquartered US company Allergan said it was mulling a bid and then quickly decided, after an unimpressed shareholder reaction, that it wasn't.
As news of the improved offer broker on Friday, Shire shares essentially shrugged. Having earlier fallen more than 4% to below 3,800p after the Allergan interest faded, the price perked up 3,847.5p but could not hold that level for long.
Earlier on Friday, analysts at Societe Generale suggested that, based on recent takeover multiples in the sector, Takeda could raise its cash component by another £9 per Shire share from its £46.50 bid.
SocGen dissmised other potential suitors, saying neither Novartis nor AbbVie "strategically need" to buy Shire and that Pfizer is "no longer interested in transformational M&A", while Celgene and Allergan would have to raise so much new equity as to "excessively dilute" their earnings.
UBS also earlier pointed out that the deal is a "real financial stretch" for Takeda, which is likely to be "price sensitive".
The Swiss bank said it feels a deal "more likely than not a deal gets done, but who precisely does the deal remains murky", with the possibility that other bidders could still emerge and that Shire investors are likely to be "keen to avoid the regret they might feel if they don't sell and then the stock does badly" as regret avoidance "can be a powerful motivator".
Related share prices |
---|
Shire Plc (SHP) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price